-
1
-
-
0034864799
-
Proteasome inhibitors: From research tools to drug candidates
-
Kisselev A.F., Goldberg A.L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 8:2001;739-758.
-
(2001)
Chem. Biol.
, vol.8
, pp. 739-758
-
-
Kisselev, A.F.1
Goldberg, A.L.2
-
2
-
-
0029556491
-
Catalytic mechanism of the 20S proteasome of Thermoplasma acidophilum revealed by X-ray crystallography
-
Stock D., et al. Catalytic mechanism of the 20S proteasome of Thermoplasma acidophilum revealed by X-ray crystallography. Cold Spring Harb. Symp. Quant. Biol. 60:1995;525-532.
-
(1995)
Cold Spring Harb. Symp. Quant. Biol.
, vol.60
, pp. 525-532
-
-
Stock, D.1
-
3
-
-
0030854371
-
Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin
-
Desai S.D., et al. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J. Biol. Chem. 272:1997;24159-24164.
-
(1997)
J. Biol. Chem.
, vol.272
, pp. 24159-24164
-
-
Desai, S.D.1
-
4
-
-
0034193276
-
Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs
-
Ogiso Y., et al. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res. 60:2000;2429-2434.
-
(2000)
Cancer Res.
, vol.60
, pp. 2429-2434
-
-
Ogiso, Y.1
-
5
-
-
0033817518
-
Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341
-
Frankel A., et al. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin. Cancer Res. 6:2000;3719-3728.
-
(2000)
Clin. Cancer Res.
, vol.6
, pp. 3719-3728
-
-
Frankel, A.1
-
6
-
-
0343091329
-
Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation
-
Masdehors P., et al. Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation. Leuk. Lymphoma. 38:2000;499-504.
-
(2000)
Leuk. Lymphoma
, vol.38
, pp. 499-504
-
-
Masdehors, P.1
-
7
-
-
0029024015
-
Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
-
Pagano M., et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 269:1995;682-685.
-
(1995)
Science
, vol.269
, pp. 682-685
-
-
Pagano, M.1
-
8
-
-
12944283204
-
Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma
-
Chiarle R., et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood. 95:2000;619-626.
-
(2000)
Blood
, vol.95
, pp. 619-626
-
-
Chiarle, R.1
-
9
-
-
17744375952
-
Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27
-
Waltregny D., et al. Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol. Endocrinol. 15:2001;765-782.
-
(2001)
Mol. Endocrinol.
, vol.15
, pp. 765-782
-
-
Waltregny, D.1
-
10
-
-
0035328584
-
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition
-
Cusack J.C. Jr, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 61:2001;3535-3540.
-
(2001)
Cancer Res.
, vol.61
, pp. 3535-3540
-
-
Cusack J.C. Jr1
-
11
-
-
0032429122
-
Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts
-
An B., et al. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. 5:1998;1062-1075.
-
(1998)
Cell Death Differ.
, vol.5
, pp. 1062-1075
-
-
An, B.1
-
12
-
-
0033068154
-
The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro
-
Winston J.T., et al. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev. 13:1999;270-283.
-
(1999)
Genes Dev.
, vol.13
, pp. 270-283
-
-
Winston, J.T.1
-
13
-
-
0033083158
-
Signal-induced ubiquitination of IkappaBalpha by the F-box protein Slimb/beta-TrCP
-
Spencer E., et al. Signal-induced ubiquitination of IkappaBalpha by the F-box protein Slimb/beta-TrCP. Genes Dev. 13:1999;284-294.
-
(1999)
Genes Dev.
, vol.13
, pp. 284-294
-
-
Spencer, E.1
-
14
-
-
0028970734
-
Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway
-
Alkalay I., et al. Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U. S. A. 92:1995;10599-10603.
-
(1995)
Proc. Natl. Acad. Sci. U. S. A.
, vol.92
, pp. 10599-10603
-
-
Alkalay, I.1
-
15
-
-
0030041147
-
Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B
-
Chauhan D., et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood. 87:1996;1104-1112.
-
(1996)
Blood
, vol.87
, pp. 1104-1112
-
-
Chauhan, D.1
-
16
-
-
0036624741
-
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: Therapeutic applications
-
Mitsiades N., et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 99:2002;4079-4086.
-
(2002)
Blood
, vol.99
, pp. 4079-4086
-
-
Mitsiades, N.1
-
17
-
-
0032588317
-
NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis
-
Wang C.Y., et al. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol. Cell. Biol. 19:1999;5923-5929.
-
(1999)
Mol. Cell. Biol.
, vol.19
, pp. 5923-5929
-
-
Wang, C.Y.1
-
18
-
-
0033621956
-
The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L)
-
Chen C., et al. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol. Cell. Biol. 20:2000;2687-2695.
-
(2000)
Mol. Cell. Biol.
, vol.20
, pp. 2687-2695
-
-
Chen, C.1
-
19
-
-
0033177897
-
NF-kappaB and chemoresistance: Potentiation of cancer drugs via inhibition of NF-kappaB
-
Cusack J.C., et al. NF-kappaB and chemoresistance: potentiation of cancer drugs via inhibition of NF-kappaB. Drug Resist. Updates. 2:1999;271-273.
-
(1999)
Drug Resist. Updates
, vol.2
, pp. 271-273
-
-
Cusack, J.C.1
-
20
-
-
0033565217
-
Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo
-
Duffey D.C., et al. Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res. 59:1999;3468-3474.
-
(1999)
Cancer Res.
, vol.59
, pp. 3468-3474
-
-
Duffey, D.C.1
-
21
-
-
0035207110
-
The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma
-
Berenson J.R., et al. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin. Oncol. 28:2001;626-633.
-
(2001)
Semin. Oncol.
, vol.28
, pp. 626-633
-
-
Berenson, J.R.1
-
22
-
-
0032905030
-
Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB
-
Wang C.Y., et al. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med. 5:1999;412-417.
-
(1999)
Nat. Med.
, vol.5
, pp. 412-417
-
-
Wang, C.Y.1
-
23
-
-
0032539702
-
Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
-
Adams J., et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. 8:1998;333-338.
-
(1998)
Bioorg. Med. Chem. Lett.
, vol.8
, pp. 333-338
-
-
Adams, J.1
-
24
-
-
0032189685
-
Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor
-
Orlowski R.Z., et al. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. 58:1998;4342-4348.
-
(1998)
Cancer Res.
, vol.58
, pp. 4342-4348
-
-
Orlowski, R.Z.1
-
25
-
-
0034237661
-
Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition
-
Pajonk F., et al. Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition. Int. J. Radiat. Oncol. Biol. Phys. 47:2000;1025-1032.
-
(2000)
Int. J. Radiat. Oncol. Biol. Phys.
, vol.47
, pp. 1025-1032
-
-
Pajonk, F.1
-
26
-
-
0035864344
-
Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin
-
Arlt A., et al. Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene. 20:2001;859-868.
-
(2001)
Oncogene
, vol.20
, pp. 859-868
-
-
Arlt, A.1
-
27
-
-
0035422206
-
Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells
-
Desai S.D., et al. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res. 61:2001;5926-5932.
-
(2001)
Cancer Res.
, vol.61
, pp. 5926-5932
-
-
Desai, S.D.1
-
28
-
-
0033802887
-
Synergistic cytotoxic interactions between sodium butyrate, MG132 and camptothecin in human retinoblastoma Y79 cells
-
Lauricella M., et al. Synergistic cytotoxic interactions between sodium butyrate, MG132 and camptothecin in human retinoblastoma Y79 cells. Tumour Biol. 21:2000;337-348.
-
(2000)
Tumour Biol.
, vol.21
, pp. 337-348
-
-
Lauricella, M.1
-
29
-
-
0033865860
-
Synergistic antitumor effects of a selective proteasome inhibitor and TNF in mice
-
Golab J., et al. Synergistic antitumor effects of a selective proteasome inhibitor and TNF in mice. Anticancer Res. 20:2000;1717-1721.
-
(2000)
Anticancer Res.
, vol.20
, pp. 1717-1721
-
-
Golab, J.1
-
30
-
-
0035866355
-
CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice
-
Sun J., et al. CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. Cancer Res. 61:2001;1280-1284.
-
(2001)
Cancer Res.
, vol.61
, pp. 1280-1284
-
-
Sun, J.1
-
31
-
-
0031906567
-
The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis
-
Delic J., et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br. J. Cancer. 77:1998;1103-1107.
-
(1998)
Br. J. Cancer
, vol.77
, pp. 1103-1107
-
-
Delic, J.1
-
32
-
-
0035215010
-
Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia
-
Zhang L., et al. Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke. 32:2001;2926-2931.
-
(2001)
Stroke
, vol.32
, pp. 2926-2931
-
-
Zhang, L.1
-
33
-
-
0033918122
-
Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia
-
Phillips J.B., et al. Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia. Stroke. 31:2000;1686-1693.
-
(2000)
Stroke
, vol.31
, pp. 1686-1693
-
-
Phillips, J.B.1
-
34
-
-
0036379624
-
Early clinical experience with the novel proteasome inhibitor PS-519
-
Shah I.M., et al. Early clinical experience with the novel proteasome inhibitor PS-519. Br. J. Clin. Pharmacol. 54:2002;269-276.
-
(2002)
Br. J. Clin. Pharmacol.
, vol.54
, pp. 269-276
-
-
Shah, I.M.1
-
35
-
-
0033152760
-
Proteasome inhibitors: A novel class of potent and effective antitumor agents
-
Adams J., et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59:1999;2615-2622.
-
(1999)
Cancer Res.
, vol.59
, pp. 2615-2622
-
-
Adams, J.1
-
36
-
-
0032885416
-
The proteasome inhibitor PS-341 in cancer therapy
-
Teicher B.A., et al. The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. 5:1999;2638-2645.
-
(1999)
Clin. Cancer Res.
, vol.5
, pp. 2638-2645
-
-
Teicher, B.A.1
-
37
-
-
0034902354
-
Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappaB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma
-
Sunwoo J.B., et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappaB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 7:2001;1419-1428.
-
(2001)
Clin. Cancer Res.
, vol.7
, pp. 1419-1428
-
-
Sunwoo, J.B.1
-
38
-
-
0034788065
-
Molecular pathways that modify tumor radiation response
-
Pervan M., et al. Molecular pathways that modify tumor radiation response. Am. J. Clin. Oncol. 24:2001;481-485.
-
(2001)
Am. J. Clin. Oncol.
, vol.24
, pp. 481-485
-
-
Pervan, M.1
-
39
-
-
0035341494
-
Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kB
-
Russo S.M., et al. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kB. Int. J. Radiat. Oncol. Biol. Phys. 50:2001;183-193.
-
(2001)
Int. J. Radiat. Oncol. Biol. Phys.
, vol.50
, pp. 183-193
-
-
Russo, S.M.1
-
40
-
-
0000640680
-
PS-341 enhances chemotherapeutic effect in human xenograft models
-
Abstract
-
Pink, M. et al. (2002) PS-341 enhances chemotherapeutic effect in human xenograft models, Proc. Am. Assoc. Cancer Res. 43, 158 (Abstract).
-
(2002)
Proc. Am. Assoc. Cancer Res.
, vol.43
, pp. 158
-
-
Pink, M.1
-
41
-
-
0012383819
-
Docetaxel followed by PS-341 results in phosphorylation and stabilization of p27 and increases response in non-small cell lung carcinoma (NSCLC)
-
Gumerlock P.H., et al. Docetaxel followed by PS-341 results in phosphorylation and stabilization of p27 and increases response in non-small cell lung carcinoma (NSCLC). Clin. Cancer Res. 7:2001;157.
-
(2001)
Clin. Cancer Res.
, vol.7
, pp. 157
-
-
Gumerlock, P.H.1
-
42
-
-
0035300479
-
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
-
Hideshima T., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61:2001;3071-3076.
-
(2001)
Cancer Res.
, vol.61
, pp. 3071-3076
-
-
Hideshima, T.1
-
43
-
-
79960971274
-
Generation of PS-341-adapted human multiple myeloma cells as experimental tools for analysis of proteasome function in cancer
-
Abstract
-
Steiner, P. et al. (2001) Generation of PS-341-adapted human multiple myeloma cells as experimental tools for analysis of proteasome function in cancer. Blood 98, 310a (Abstract).
-
(2001)
Blood
, vol.98
-
-
Steiner, P.1
-
44
-
-
0036735298
-
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model
-
LeBlanc R., et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62:2002;4996-5000.
-
(2002)
Cancer Res.
, vol.62
, pp. 4996-5000
-
-
LeBlanc, R.1
-
45
-
-
0036023407
-
A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies
-
Aghajanian C., et al. A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 8:2002;2505-2511.
-
(2002)
Clin. Cancer Res.
, vol.8
, pp. 2505-2511
-
-
Aghajanian, C.1
-
46
-
-
0000481441
-
Phase I study of the proteasome inhibitor bortezomib (PS-341, Velcade™) in combination with pegylated liposomal doxorubicin (Doxil®) in patients with refractory hematologic malignancies
-
Orlowski R.Z., et al. Phase I study of the proteasome inhibitor bortezomib (PS-341, Velcade™) in combination with pegylated liposomal doxorubicin (Doxil®) in patients with refractory hematologic malignancies. Blood. 100:2002;105a.
-
(2002)
Blood
, vol.100
-
-
Orlowski, R.Z.1
-
47
-
-
0001100607
-
Pharmacokinetic and pharmacodynamic Phase I study of PS-341 and gemcitabine in patients with advanced solid tumors
-
Ryan, D.P. et al. (2002) Pharmacokinetic and pharmacodynamic Phase I study of PS-341 and gemcitabine in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol.38th Annual Meeting 21, 95a.
-
(2002)
Proc. Am. Soc. Clin. Oncol. 38th Annual Meeting
, vol.21
-
-
Ryan, D.P.1
-
48
-
-
0001100610
-
Phase I dose-escalation study of the proteasome inhibitor, PS-341, plus irinotecan in patients with advanced solid tumors
-
Clark, J.W. et al. (2002) Phase I dose-escalation study of the proteasome inhibitor, PS-341, plus irinotecan in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 38th Annual Meeting 21, 93a.
-
(2002)
Proc. Am. Soc. Clin. Oncol. 38th Annual Meeting
, vol.21
-
-
Clark, J.W.1
-
49
-
-
0003305854
-
Dose-dependent inhibition of 20S proteasome results in serum IL-6 and PSA decline in patients (pts) with androgen-independent prostate cancer (AI PCa) treated with the proteasome inhibitor PS-341
-
Logothetis, C.J. et al. (2001) Dose-dependent inhibition of 20S proteasome results in serum IL-6 and PSA decline in patients (pts) with androgen-independent prostate cancer (AI PCa) treated with the proteasome inhibitor PS-341. Proc. Am. Soc. Clin. Oncol. 37th Annual Meeting 20, 186a.
-
(2001)
Proc. Am. Soc. Clin. Oncol. 37th Annual Meeting
, vol.20
-
-
Logothetis, C.J.1
-
50
-
-
0001343234
-
Phase I study of PS-341, a novel proteasome inhibitor, in patients with advanced malignancies
-
Papandreou, C.N. et al. (2000) Phase I study of PS-341, a novel proteasome inhibitor, in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol. 36th Annual Meeting 19, 190a.
-
(2000)
Proc. Am. Soc. Clin. Oncol. 36th Annual Meeting
, vol.19
-
-
Papandreou, C.N.1
-
51
-
-
0003208559
-
PS-341: Phase I study of a novel proteasome inhibitor with pharmacodynamic endpoints
-
Hamilton, A.L. et al. (2001) PS-341: Phase I study of a novel proteasome inhibitor with pharmacodynamic endpoints. Proc. Am. Soc. Clin. Oncol. 37th Annual Meeting 20, 85a.
-
(2001)
Proc. Am. Soc. Clin. Oncol. 37th Annual Meeting
, vol.20
-
-
Hamilton, A.L.1
-
52
-
-
0003230750
-
Phase II study of the proteasome inhibitor PS-341 in multiple myeloma patients (pts) with relapsed/refractory disease: results from cohort 1 analysis
-
Richardson, P.G. et al. (2002) Phase II study of the proteasome inhibitor PS-341 in multiple myeloma patients (pts) with relapsed/refractory disease: results from cohort 1 analysis. Proc. Am. Soc. Clin. Oncol. 38th Annual Meeting 21, 11a.
-
(2002)
Proc. Am. Soc. Clin. Oncol. 38th Annual Meeting
, vol.21
-
-
Richardson, P.G.1
-
53
-
-
0003320840
-
PS-341 is active in multiple myeloma: Preliminary report of a Phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies
-
Stinchcombe T.E., et al. PS-341 is active in multiple myeloma: Preliminary report of a Phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies. Blood. 96:2000;516a.
-
(2000)
Blood
, vol.96
-
-
Stinchcombe, T.E.1
-
54
-
-
0000481440
-
A Phase II multicenter study of the proteasome inhibitor bortezomib (Velcade™ formerly PS-341) in multiple myeloma patients (pts) with relapsed/refractory disease
-
Richardson P., et al. A Phase II multicenter study of the proteasome inhibitor bortezomib (Velcade™ formerly PS-341) in multiple myeloma patients (pts) with relapsed/refractory disease. Blood. 100:2002;104a.
-
(2002)
Blood
, vol.100
-
-
Richardson, P.1
-
55
-
-
0035798622
-
26 S proteasome-mediated degradation of topoisomerase II cleavable complexes
-
Mao Y., et al. 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes. J. Biol. Chem. 276:2001;40652-40658.
-
(2001)
J. Biol. Chem.
, vol.276
, pp. 40652-40658
-
-
Mao, Y.1
-
56
-
-
0034607655
-
Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli
-
Yang Y., et al. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science. 288:2000;874-877.
-
(2000)
Science
, vol.288
, pp. 874-877
-
-
Yang, Y.1
-
57
-
-
0034635952
-
Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression
-
Li B., Dou Q.P. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc. Natl. Acad. Sci. U. S. A. 97:2000;3850-3855.
-
(2000)
Proc. Natl. Acad. Sci. U. S. A.
, vol.97
, pp. 3850-3855
-
-
Li, B.1
Dou, Q.P.2
-
58
-
-
0033533499
-
Phosphorylation and proteasome-dependent degradation of Bcl-2 in mitotic-arrested cells after microtubule damage
-
Chadebech P., et al. Phosphorylation and proteasome-dependent degradation of Bcl-2 in mitotic-arrested cells after microtubule damage. Biochem. Biophys. Res. Commun. 262:1999;823-827.
-
(1999)
Biochem. Biophys. Res. Commun.
, vol.262
, pp. 823-827
-
-
Chadebech, P.1
-
59
-
-
0033833068
-
Pyk2 and FAK differentially regulate progression of the cell cycle
-
Zhao J., et al. Pyk2 and FAK differentially regulate progression of the cell cycle. J. Cell Sci. 113:2000;3063-3072.
-
(2000)
J. Cell Sci.
, vol.113
, pp. 3063-3072
-
-
Zhao, J.1
-
60
-
-
0034597619
-
Cut8, essential for anaphase, controls localization of 26S proteasome, facilitating destruction of cyclin and Cut2
-
Tatebe H., Yanagida M. Cut8, essential for anaphase, controls localization of 26S proteasome, facilitating destruction of cyclin and Cut2. Curr. Biol. 10:2000;1329-1338.
-
(2000)
Curr. Biol.
, vol.10
, pp. 1329-1338
-
-
Tatebe, H.1
Yanagida, M.2
-
61
-
-
0029957947
-
Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation
-
Clurman B.E., et al. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev. 10:1996;1979-1990.
-
(1996)
Genes Dev.
, vol.10
, pp. 1979-1990
-
-
Clurman, B.E.1
-
62
-
-
0032511893
-
Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21
-
Cayrol C., Ducommun B. Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene. 17:1998;2437-2444.
-
(1998)
Oncogene
, vol.17
, pp. 2437-2444
-
-
Cayrol, C.1
Ducommun, B.2
-
63
-
-
0030810984
-
The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin
-
Segnitz B., Gehring U. The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin. J. Biol. Chem. 272:1997;18694-18701.
-
(1997)
J. Biol. Chem.
, vol.272
, pp. 18694-18701
-
-
Segnitz, B.1
Gehring, U.2
-
64
-
-
0033551374
-
MYC oncogenes and human neoplastic disease
-
Nesbit C.E., et al. MYC oncogenes and human neoplastic disease. Oncogene. 18:1999;3004-3016.
-
(1999)
Oncogene
, vol.18
, pp. 3004-3016
-
-
Nesbit, C.E.1
-
65
-
-
0032787671
-
Degradation of Id proteins by the ubiquitin-proteasome pathway
-
Bounpheng M.A., et al. Degradation of Id proteins by the ubiquitin-proteasome pathway. FASEB J. 13:1999;2257-2264.
-
(1999)
FASEB J.
, vol.13
, pp. 2257-2264
-
-
Bounpheng, M.A.1
-
66
-
-
0027980321
-
The ubiquitin-proteasome pathway is required for processing the NF- kappa B1 precursor protein and the activation of NF-kappa B
-
Palombella V.J., et al. The ubiquitin-proteasome pathway is required for processing the NF- kappa B1 precursor protein and the activation of NF-kappa B. Cell. 78:1994;773-785.
-
(1994)
Cell
, vol.78
, pp. 773-785
-
-
Palombella, V.J.1
-
67
-
-
0029952441
-
In vivo ubiquitination and proteasome-mediated degradation of p53(1)
-
Maki C.G., et al. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 56:1996;2649-2654.
-
(1996)
Cancer Res.
, vol.56
, pp. 2649-2654
-
-
Maki, C.G.1
-
68
-
-
0029834371
-
E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway
-
Boyer S.N., et al. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 56:1996;4620-4624.
-
(1996)
Cancer Res.
, vol.56
, pp. 4620-4624
-
-
Boyer, S.N.1
-
69
-
-
0034875305
-
Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome
-
Bold R.J., et al. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J. Surg. Res. 100:2001;11-17.
-
(2001)
J. Surg. Res.
, vol.100
, pp. 11-17
-
-
Bold, R.J.1
-
70
-
-
0003346451
-
Antitumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells
-
Abstract
-
Pham L., et al. Antitumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells. Blood. 98:2001;465a. Abstract.
-
(2001)
Blood
, vol.98
-
-
Pham, L.1
-
71
-
-
0034981649
-
26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer
-
Shah S.A., et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell. Biochem. 82:2001;110-122.
-
(2001)
J. Cell. Biochem.
, vol.82
, pp. 110-122
-
-
Shah, S.A.1
-
72
-
-
0036172154
-
Proteasome inhibitor PS-341, a potential therapeutic agent for adult T- cell leukemia
-
Tan C., Waldmann T.A. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T- cell leukemia. Cancer Res. 62:2002;1083-1086.
-
(2002)
Cancer Res.
, vol.62
, pp. 1083-1086
-
-
Tan, C.1
Waldmann, T.A.2
|